Growth factors in the treatment of diabetic foot syndrome
https://doi.org/10.14341/DM10130
Abstract
Growth factors play a key role in wound healing, deficiency of which leads to delayed healing. Various growth factors are used in the treatment of chronic wounds, including diabetic foot ulcers. The purpose of this review was to analyse the literature data on the effectiveness of epidermal growth factor, platelet-rich plasma and platelet growth factor in patients with diabetic foot syndrome. The effect of treatment with these growth factors on healing of diabetic foot ulcers and healing time were analysed. Published studies, mostly with low level of evidence, demonstrate a positive effect of various growth factors on the healing process of diabetic foot ulcers. Currently, there is no conclusion on the advantages of growth factor therapy. Further studies with a high level of evidence are needed to justify their use in routine clinical practice.
About the Authors
Elena Y. Komelyagina
Endocrinology department of the Moscow Health Department; Russian Medical Academy of Continuing Medical Education
Russian Federation
Russian Federation
MD, PhD
Michail B. Antsiferov
Endocrinology department of the Moscow Health Department; Russian Medical Academy of Continuing Medical Education
Russian Federation
Russian Federation
MD, PhD, Professor
References
1. Zhang J. Growth factors in the pathogenesis of diabetic foot ulcers. Front Biosci. 2018;23(1):310-317. doi: https://doi.org/10.2741/4593
2. Park JW, Hwang SR, Yoon IS. Advanced Growth Factor Delivery Systems in Wound Management and Skin Regeneration. Molecules. 2017;22(8). doi: https://doi.org/10.3390/molecules22081259
3. Patel S, Srivastava S, Singh MR, Singh D. Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed Pharmacother. 2019;112:108615. doi: https://doi.org/10.1016/j.biopha.2019.108615
4. Steed DL. Role of Growth Factors in the Treatment of Diabetic Foot Ulceration. In: Veves A, Giurini J, LoGerfo F, editors. The Diabetic Foot. 2nd ed. Totowa: Humana Press; 2006. p. 447-458.
5. Qing C. The molecular biology in wound healing & non-healing wound. Chin J Traumatol. 2017;20(4):189-193. doi: https://doi.org/10.1016/j.cjtee.2017.06.001
6. Bruhn-Olszewska B, Korzon-Burakowska A, Gabig-Ciminska M, et al. Molecular factors involved in the development of diabetic foot syndrome. Acta Biochim Pol. 2012;59(4):507-513.
7. Moustakas A, Heldin P. TGFβ and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta Gen Subj. 2014;1840(8):2621-2634. doi: https://doi.org/10.1016/j.bbagen.2014.02.004
8. Yan C, Grimm WA, Garner WL, et al. Epithelial to Mesenchymal Transition in Human Skin Wound Healing Is Induced by Tumor Necrosis Factor-α through Bone Morphogenic Protein-2. Am J Pathol. 2010;176(5):2247-2258. doi: https://doi.org/10.2353/ajpath.2010.090048
9. Yoshida M, Okubo N, Chosa N, et al. TGF-beta-operated growth inhibition and translineage commitment into smooth muscle cells of periodontal ligament-derived endothelial progenitor cells through Smad- and p38 MAPK-dependent signals. Int J Biol Sci. 2012;8(7):1062-1074. doi: https://doi.org/10.7150/ijbs.4488
10. Профилактика и лечение заболеваний стопы при диабете. Руководство, документы и рекомендации. Полная русскоязычная версия. 2016. [International Consensus on the Diabetic Foot. Russian version. 2016. (In Russ.)]
11. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555-1562.
12. Nanney LB. Epidermal and Dermal Effects of Epidermal Growth Factor During Wound Repair. J Invest Dermatol. 1990;94(5):624-629. doi: https://doi.org/10.1111/1523-1747.ep12876204
13. Tiaka EK, Papanas N, Manolakis AC, Georgiadis GS. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Perspect Vasc Surg Endovasc Ther. 2012;24(1):37-44. doi: https://doi.org/10.1177/1531003512442093
14. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585-601. doi: https://doi.org/10.1111/j.1524-475X.2008.00410.x
15. Acosta JB, Savigne W, Valdez C, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J. 2006;3(3):232-239. doi: https://doi.org/10.1111/j.1742-481X.2006.00237.x
16. Brown GL, Nanney LB, Griffen J, et al. Enhancement of Wound Healing by Topical Treatment with Epidermal Growth Factor. New Eng J Med. 1989;321(2):76-79. doi: https://doi.org/10.1056/nejm198907133210203
17. Tsang MW, Wong WKR, Hung CS, et al. Human Epidermal Growth Factor Enhances Healing of Diabetic Foot Ulcers. Diabetes Care. 2003;26(6):1856-1861. doi: https://doi.org/10.2337/diacare.26.6.1856
18. Hong JP, Jung HD, Kim YW. Recombinant Human Epidermal Growth Factor (EGF) to Enhance Healing for Diabetic Foot Ulcers. Ann Plast Surg. 2006;56(4):394-398. doi: https://doi.org/10.1097/01.sap.0000198731.12407.0c
19. Viswanathan V, Pendsey S. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D TM 150) in healing diabetic foot ulcers. Wounds. 2006;18:186-196.
20. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, et al. Intralesional injections of Citoprot-P®(recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333-343. doi: https://doi.org/10.1111/j.1742-481X.2007.00344.x
21. Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J. 2009;6(2):159-166. doi: https://doi.org/10.1111/j.1742-481X.2009.00594.x
22. Fernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6(6):432-443. doi: https://doi.org/10.1111/j.1742-481X.2009.00641.x
23. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67-72. doi: https://doi.org/10.1111/j.1742-481X.2008.00561.x
24. Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: A randomized double-blinded controlled trial. Wound Repair Regen. 2014;22(4):497-503. doi: https://doi.org/10.1111/wrr.12187
25. Henning PR, Grear BJ. Platelet-rich plasma in the foot and ankle. Curr Rev Musculoskelet Med. 2018;11(4):616-623. doi: https://doi.org/10.1007/s12178-018-9522-z
26. McCarrel TM, Minas T, Fortier LA. Optimization of Leukocyte Concentration in Platelet-Rich Plasma for the Treatment of Tendinopathy. J Bone Joint Surg. 2012;94(19):e143. doi: https://doi.org/10.2106/jbjs.l.00019
27. Knighton DR, Ciresi K, Fiegel VD, et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet. 1990;170(1):56-60.
28. Steed DL, Golsten B, Hambley R, et al. Clinical trials with purified platelet realisate. In: Barbul A, Liss A, editors. Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds. New York; 1990. p. 103-113.
29. Knighton DR, Ciresi KF, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986;204(3):322-330. doi: https://doi.org/10.1097/00000658-198609000-00011
30. Atri SC, Misra J, Bisht D, Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery. 1990;108(3):508-512.
31. Hirase T, Ruff E, Surani S, Ratnani I. Topical application of platelet-rich plasma for diabetic foot ulcers: A systematic review. World J Diabetes. 2018;9(10):172-179. doi: https://doi.org/10.4239/wjd.v9.i10.172
32. Просянникова Н.В. Аутологичная, богатая тромбоцитами плазма, в лечении язвенных поражений кожи нижних конечностей: Дис. … канд. мед. наук. — М.; 2014. [Prosyannikova NV. Autologichnaya, bogataya trombotsitami plazma, v lechenii yazvennykh porazheniy kozhi nizhnikh konechnostey. [dissertation] Moscow; 2014. (In Russ.)]
33. Халимов Э.В., Михайлов А.Ю., Иванова Л.М. Тромбоцитарный концентрат в комплексном лечении язвенных дефектов при синдроме диабетической стопы. В кн.: Труды Ижевской государственной медицинской академии. Т. 56. — Ижевск; 2018. — С. 57-58. [Trudy Izhevskoy gosudarstvennoy meditsinskoy akademii. Vol. 56. Izhevsk; 2018. p. 57-58. (In Russ.)]
34. Obolenskiy VN, Ermolova DA, Laberko LA. Clinical and economic effectiveness of the use of platelet-rich plasma in the treatment of chronic wounds. Wound Medicine. 2017;19:27-32. doi: https://doi.org/10.1016/j.wndm.2017.09.001
35. Serra R, Buffone G, Dominijanni A, et al. Application of platelet-rich gel to enhance healing of transmetatarsal amputations in diabetic dysvascular patients. Int Wound J. 2013;10(5):612-615. doi: https://doi.org/10.1111/iwj.12052
36. Kontopodis N, Tavlas E, Papadopoulos G, et al. Effectiveness of Platelet-Rich Plasma to Enhance Healing of Diabetic Foot Ulcers in Patients With Concomitant Peripheral Arterial Disease and Critical Limb Ischemia. Int J Low Extrem Wounds. 2016;15(1):45-51. doi: https://doi.org/10.1177/1534734615575829
37. Jeong SH, Han SK, Kim WK. Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg. 2010;125(3):944-952. doi: https://doi.org/10.1097/PRS.0b013e3181cb6589
38. Game F, Jeffcoate W, Tarnow L, et al. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):870-878. doi: https://doi.org/10.1016/s2213-8587(18)30240-7
39. Eldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med. 2004;21(11):1161-1173. doi: https://doi.org/10.1111/j.1464-5491.2004.01358.x
40. Falanga V. New treatment for diabetic foot ulcers (a) growth factors. In: Boulton AJ, Connor H, Cavanagh P, editors. The Foot in Diabetes. 3rd ed. Chichester: John Wiley &Sons; 2000. p. 169-178.
41. Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf. 2010;33(6):455-461. doi: https://doi.org/10.2165/11534570-000000000-00000
42. Профилактика и лечение заболеваний стопы при диабете. Руководство, документы и рекомендации. Полная русскоязычная версия. 2016. [International Consensus on the Diabetic Foot. Russian version. 2016. (In Russ.)]
43. Marti-Carvajal AJ, Gluud C, Nicola S, et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2015(10):CD008548. doi: https://doi.org/10.1002/14651858.CD008548.pub2
Supplementary files
Review
For citations:
Komelyagina E.Y., Antsiferov M.B. Growth factors in the treatment of diabetic foot syndrome. Diabetes mellitus. 2019;22(4):377-383. (In Russ.) https://doi.org/10.14341/DM10130
Views:
1701
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
